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Abstract The cellular prion protein of the mouse, m P r P c , 
consists of 208 amino acids (residues 23-231). It contains a 
carboxy-terminal domain, /nPrP(121-231), which represents an 
autonomous folding unit with three a-helices and a two-stranded 
antiparallel P-sheet. We expressed the complete amino acid 
sequence of the prion protein, iwPrP(23-231), in the cytoplasm of 
Escherichia coli. »iPrP(23-231) was solubilized from inclusion 
bodies by 8 M urea, oxidatively refolded and purified to 
homogeneity by conventional chromatographic techniques. Com-
parison of near-UV circular dichroism, fluorescence and one-
dimensional iH-NMR spectra of mPrP(23-231) and /nPrP(121-
231) shows that the amino-terminal segment 23-120, which 
includes the five characteristic octapeptide repeats, does not 
contribute measurably to the manifestation of three-dimensional 
structure as detected by these techniques, indicating that the 
residues 121-231 might be the only polypeptide segment of P r P c 
with a defined three-dimensional structure. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Transmissible spongiform encephalopathies (TSEs) such as 
the Creutzfeldt-Jakob disease in humans, scrapie in sheep and 
bovine spongiform encephalopathy (BSE) in cattle are be-
lieved to be caused by a novel class of infectious pathogens, 
the 'prions' [1-3]. According to the protein-only hypothesis 
[4-6], the prion consists of an abnormal oligomeric form, 
PrPS c , of the host-encoded cellular prion protein, P r P c . While 
mammalian P r P c is a highly conserved, monomeric cell sur-
face glycoprotein, PrPS c forms protease-resistant oligomers 
with amyloid characteristics [1-3,7]. P r P c and PrPS c mono-
mers appear to be identical in their covalent structures [7], 
but an increased [3-sheet content has been demonstrated for 
PrPS c when compared with P r P c [8,9]. Different kinetic mod-
els, such as the 'nucleation-polymerization' model [10] and the 
' template assistance' model [11], have been proposed for the 
mechanism of self-replication of the infectious oligomer (re-
viewed in [3]). 
The murine prion protein, mPrP(23-231), consists of 208 
amino acids (residues 23-231 in the numerat ion of P rP from 
Syrian hamster, with deletion of residue 55 [12]). It has a 
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single disulfide bond (Cys1 7 9-Cys2 1 4) , two N-glycosylation 
sites (Asn181 and Asn1 9 7) and a glycosyl-phosphatidyl-inositol 
(GPI) anchor at its carboxy-terminal Ser231 [7]. We previously 
demonstrated that the recombinant segment 121-231 of wPrP 
represents a distinct domain that folds autonomously and 
reversibly [13] and has a well-defined three-dimensional struc-
ture formed by three a-helices and a two-stranded antiparallel 
P-sheet [14]. 
The exact size of the domain mPrP(121-231) was deduced 
from the observation that expression of the PrP fragments 9 5 -
231 and 107-231 in the periplasm of Escherichia coli was 
accompanied by amino-terminal degradation, with cleavage 
at multiple sites in the segment 100-120 [13]. In this paper, 
we report the purification of the complete, recombinant mu-
rine P r P c protein with intact disulfide bond, its spectroscopic 
characterization, and comparisons of the polypeptide segment 
121-231 in full-length w P r P c with the isolated carboxy-termi-
nal domain, mPrP(121-231). 
2. Materials and methods 
2.1. Materials 
Oligonucleotides were purchased from MWG-Biotech (Ebersberg, 
Germany) and SP-Sepharose was obtained from Pharmacia (Uppsala, 
Sweden). Tryptone and yeast extract were from DIFCO (Detroit, 
USA) and isopropyl-p-D-thiogalactopyranoside (IPTG) was pur-
chased from AGS (Heidelberg, Germany). 1,4-Dithio-DL-threitol 
(DTT), phenylmethylsulfonyl fluoride (PMSF) and dithionitrobenzoic 
acid (DTNB) were purchased from Sigma-Aldricli (Deisenhofen, Ger-
many). All other chemicals were of analysis grade. 
2.2. Expression and purification of recombinant mPrP'(23-231) 
The gene coding for wPrP(23-231) was amplified by the polymerase 
chain reaction from a plasmid harboring the mPrP(23-231) cDNA 
[15] using the oligonucleotide primers as listed in Table 1. 
Table 1 
N-terminal primer 
5'-GACTGATGTCCATATGTCTAAAAAGCGTCCAAAGCCTGGAGGGTGGA-
ACACCG-3' 
C-terminal primer 
5'-AGGAGGGGAGGGGATCCAAGCTTACTAGCTGGAACGACGCCCGTCGT-
AATAGGCCTGGGACTCC-3' 
The amplified gene was cloned into the plasmid pRBI-PDI-T7 [16] 
via the Ndel and BamHl restricition sites. In the resulting expression 
plasmid, termed pPrP(23-231), the PrP gene is under control of the 
T7 promoter/lac operator sequence. As recombinant mPrP(121-231) 
[13], the polypeptide expressed with pPrP(23-231) contains an addi-
tional Ser at the carboxy-terminus. According to the N-end rule in 
bacteria [17], we also introduced a Ser at the amino-terminus of 
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mPrP(23-231) to minimize proteolytic degradation in the cytoplasm. 
Thus, recombinant mPrP(23-231) used in this study consists of 210 
amino acids. The correct sequence of the amplified gene in pPrP(23-
231) was verified by dideoxy sequencing. 
For the production of unlabeled mPrP(23-231) and uniformly 
16N-labeled mPrP(23-231), cells of E. coli BL21(DE3) [18] harboring 
pPrP(23-231) were grown at 37°C in 10 1 LB medium, or in 10 1 
minimal medium with unlabeled glucose (5 g/1) and (16NH4)2S04 
(1 g/1), respectively. All media contained ampicillin (100 ug/ml). At 
an optical density at 550 nm of 1.0-1.3 (rich medium) or 0.9-1.1 
(minimal medium), IPTG was added to a final concentration of 
1 mM and the cultures were grown for another 16 h. The cells were 
harvested by centrifugation and suspended in 100 ml 150 mM NaCl, 
5 mM EDTA, 50 mM Tris/HCl pH 8.0 supplemented with 1 mM 
PMSF and two protease inhibitor cocktail tablets ('COMPLETE' 
(EDTA free); Boehringer Mannheim, Germany). The bacteria were 
disrupted in a French Pressure cell (18000 PSI) and the lysate was 
centrifuged (4°C, 39000Xg, 1 h). The insoluble inclusion bodies were 
washed twice with the above buffer and solubilized in 100 ml 8 M 
urea, 10 mM Tris/HCl pH 8.0, 1 mM EDTA, 10 mM DTT. After 
centrifugation (39 000 X g, 22°C, 1 h) the pH of the supernatant was 
adjusted to 7.0 with HC1 and applied to a SP-Sepharose column 
(20 ml) equilibrated with 8 M urea, 10 mM MOPS/NaOH pH 7.0. 
wPrP(23-231) was eluted with a linear NaCl gradient (400 ml, 
0-600 mM). Fractions containing mPrP(23-231) were combined and 
the protein was reduced with 10 mM DTT at pH 8.0 (10 mM Tris/ 
HC1) for 1 h at 37°C. After addition of 10% (v/v) acetic acid the 
solution was applied to a SP-Sepharose column (20 ml) equilibrated 
with 8 M urea, 100 mM NaCl, 10% (v/v) acetic acid, then washed with 
8 M urea, 10 mM MOPS/NaOH pH 7.0, and eluted with a linear 
NaCl gradient (400 ml, 100-600 mM NaCl). 
Oxidation of mPrP(23-231) was performed for 3-16 h at 22°C at a 
protein concentration of 0.1 mg/ml in 8 M urea containing 50 mM 
Tris/HCl pH 8.7 and 1 (xM CUSO4. The reaction was analyzed by 
separation of acid-quenched samples (pH<2) on an analytical re-
versed-phase HPLC column (Vydac C18, 4.6x250 mm) at 55°C 
with a linear gradient from 28% to 40% (v/v) acetonitrile in 0.1% 
(v/v) trifluoroacetic acid (TFA). After addition of one protease inhib-
itor tablet, 10 uM EDTA and 10 uM PMSF, the denaturant was 
removed by dialysis against distilled water. Unfolded proteins were 
precipitated by addition of 10 mM sodium phosphate pH 7.0, 10 uM 
EDTA and 10 uM PMSF, and the precipitate was removed by cen-
trifugation (39 000 X g, 30 min, 4°C). The supernatant was applied to a 
SP-Sepharose column (15 ml) and mPrP(23-231) was eluted with a 
linear NaCl gradient (300 ml; 200-600 mM). Fractions containing 
homogeneous mPrP(23-231) were pooled and dialyzed against dis-
tilled water. The preparations were concentrated by ultrafiltration 
(Amicon YM10) to a volume of 50 ml. For storage, a protease in-
hibitor tablet was added and the preparation was adjusted to 10 uM 
PMSF, 0.1 uM pepstatin and 10 uM EDTA. 50 mg of unlabeled and 
25 mg of uniformly 15N-labeled mPrP(23-231) were obtained with this 
protocol. 
Edman sequencing of mPrP(23-231) revealed that the methionine at 
the amino-terminus had been cleaved off quantitatively (sequence 
found: SKKRPKPGGWNTGGS). The mass of the unlabeled 
wPrP(23-231) was verified by electrospray mass spectrometry (calcu-
lated mass: 23 107 Da; measured: 23 113 Da). Purified mPrP(23-231) 
was completely oxidized, as shown by analytical HPLC and by the 
lack of free thiols in Ellman's assay [19] after unfolding. 
2.3. Protein concentrations 
Protein concentrations were measured by the absorbance at 280 nm 
[20]. Specific absorbances (^sonm. img/mi, icm) of 2.70 and 1.55 were 
used for wPrP(23-231) and mPrP(121-231), respectively. 
2.4. Circular dichroism and fluorescence spectroscopy 
Spectroscopic measurements were performed at 22°C with filtered 
buffer solutions (0.2 |im pore size). Far-UV and near-UV circular 
dichroism spectra were recorded on a Jasco J-710 spectropolarimeter 
at protein concentrations of 0.2-0.5 mg/ml in 50 mM sodium phos-
phate pH 7.0. The spectra were recorded in a 0.2 mm cuvette in the 
far-UV region (180-250 nm) and in a 10 mm cuvette in the near-UV 
region (250-350 nm). 
Fluorescence measurements were carried out with a Hitachi F-4500 
fluorescence spectrophotometer in 0.4X1 cm cuvettes. An excitation 
wavelength of 280 nm was used in all experiments. 
2.5. NMR measurements 
'H-NMR spectra of mPrP(23-231) and mPrP(121-231) were re-
corded on a Varian UNITYplus spectrometer at a 1H frequency of 
750 MHz with 0.8 mM protein concentration in a mixed solvent of 
90% H2O/10%D2O, pH 4.5 at 20°C. The acquisition time was 0.2 s, 
and the spectral range was 10000 Hz. 
3. Results and discussion 
3.1. Cytoplasmic expression, oxidative refolding and 
purification of mPrP(23-231) 
To obtain the recombinant murine prion protein raPrP(23-
231) with intact disulfide bond, we initially tried to express the 
protein in the periplasm of E. coli using the OmpA signal 
sequence. Although this expression system allows the produc-
tion of soluble mPrP(121-231) in the E. coli periplasm [13], we 
were not able to detect a protein band corresponding to 
mPrP(23-231) in SDS-polyacrylamide gels, neither in the peri-
plasmic fraction nor in the insoluble fraction of induced E. coli 
cells. Similar observations have recently been reported for the 
periplasmic expression of hamster PrP(23-231) [21]. 
Eventually, mPrP(23-231) was expressed in the cytoplasm 
of E. coli BL21(DE3) under the control of the T7 promoter/ 
lac operator system [18]. We thus obtained large amounts of 
reduced recombinant mPrP(23-231), which accumulated in 
insoluble inclusion bodies. The inclusion bodies were solu-
bilized in 8 M urea, and ?wPrP(23-231) was purified by cation 
exchange chromatography in the presence of urea. Oxidation 
of the single disulfide bond by air oxygen was achieved at 
pH 8.7 in 8 M urea with 1 |J,M Cu2+ as a catalyst, using 
low protein concentration to avoid formation of intermolecu-
lar disulfide bonds. The reaction was monitored by analytical 
HPLC and the denaturant was subsequently removed by 
dialysis. raPrP(23-231) with intact disulfide bond was then 
purified to homogeneity by cation exchange chromatography 
at pH 7.0 under non-denaturing conditions (Fig. 1). Overall, 
5 mg of homogeneous mPrP(23-231) were obtained per liter 
of bacterial culture with rich medium, and 2.5 mg per liter for 
growth in minimal medium with 15N-ammonium sulfate 
as the sole nitrogen source. mPrP(23-231) proved to be solu-
ble in H2O at concentrations of 1.5 mM between pH 4.0 and 
7.0. 
Recombinant mPrP(23-231) was found to be rather sensi-
tive towards proteolytic digestion. Therefore, protease inhib-
itors were added during the purification of the protein. In the 
absence of protease inhibitors, we found proteolytic cleavage 
after residues 116, 118, and 120 (Fig. IB). Long-term incuba-
tion of mPrP(23-231) at 20°C and pH 4.5 in the absence of 
protease inhibitors resulted in complete degradation of the 
amino-terminal polypeptide segment 23-120, while the car-
boxy-terminal domain was not degraded. 
3.2. Circular dichroism and fluorescence spectra 
The amino-terminal region of mammalian prion proteins 
comprising residues 23-120 contains a segment of 40 amino 
acids (residues 51-91 in mPrP) that consists of 5 octapeptide 
repeats with the consensus sequence PHGGG(S)WGQ [22]. 
Due to the high content of Gly residues, regular secondary 
structure predictions for residues 51-91 of PrP did not yield 
conclusive results [23]. To analyze the contents of secondary 
and tertiary structure in the amino-terminal segment 23-120 
of recombinant mPrP(23-231), we compared its far-UV and 
near-UV circular dichroism and fluorescence spectra with 
S. Hornemann et al.lFEBS Letters 413 (1997) 277-281 279 
Fig. 1. Purification of >wPrP(23-231). A Coomassie-stained 15% polyacryl-amide/SDS gel is shown in (A). Lanes: 1, molecular mass standard; 
lane 2, solubilized inclusion bodies prepared from E. coli BL21(DE3)/pPrP(23-231); 3, recombinant mPrP(23-231) after oxidative refolding and 
purification; 4, purified mPrP(121-231). (B) Proteolytic cleavage of/«PrP(23-231) after prolonged incubation at pH 4.5 and 20°C at a protein 
concentration of 1 mM in the absence of protease inhibitors. Lanes: 1, Cleavage products of PrP(23-231) (the main cleavage site is after resi-
due 118); 2, Molecular mass standard. 
those of raPrP(121-231). Both mPrP(23-231) and mPrP(121-
231) exhibit typical a-helical far-UV CD spectra, with minima 
at 222 and 208 nm (Fig. 2A). Although the shapes of the 
spectra are very similar, the mean residue ellipticities of full-
length mPrP are significantly less negative than those of its 
carboxy-terminal domain, indicating that the percentage of 
residues located in regular secondary structures is higher in 
mPrP(121-231) than in the full-length protein. In accordance, 
the recently reported mean residue ellipticities of the segment 
90-231 of hamster PrP are also less negative in the far-UV 
region when compared with raPrP(121-231) [24]. 
Corresponding observations were made for the near-UV 
CD spectra of mPrP(23-231) and wPrP(121-231) (Fig. 2B), 
where spectra of similar shape but lower mean residue ellip-
ticities were obtained for mPrP(23-231) when compared to 
mPrP(121-231). Since the near-UV CD data relate to the ter-
tiary structure of a protein [25], this would be compatible with 
the assumptions that the structure of the carboxy-terminal 
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Fig. 2. Far-UV and near-UV circular dichroism spectra of raPrP(23-231) (solid line) and mPrP(121-231) (dashed line). Spectra were recorded 
at 22°C in 50 mM sodium phosphate pH 7.0. (A) Far-UV CD spectrum. (B) Near-UV CD spectrum. 
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Fig. 3. Fluorescence spectra of mPrP(23-231) (solid line) and 
mPrP(121-231) (dashed line) at 22°C in 50 mM sodium phosphate 
pH 7.0. Identical protein concentrations of 0.75 |xM were used. The 
excitation wavelength was 280 nm. 
be compatible with a situation where the structure observed 
for the isolated domain mPrP(121-231) would be largely re-
tained in mPrP(23-231). 
3.4. Conclusions 
Biophysical and structural studies on the cellular prion pro-
tein have been hampered in the past by the lack of an efficient 
expression and purification system that allows the production 
of milligram quantities of homogeneous PrP with intact disul-
fide bond. We believe that the protocol presented in this 
study, i.e. production of mPrP in the cytoplasm of E. coli, 
oxidative refolding from solubilized inclusion bodies and pu-
rification by conventional chromatography, provides a suit-
able tool for obtaining large quantities of pure PrPc for bio-
chemical experiments and isotope-labeled PrPc for NMR 
studies. Similar to mPrP(121-231) [13,14], mPrP(23-231) is 
soluble and does not aggregate irreversibly in aqueous solu-
tion. Its solubility between pH 4 and pH 7 is a 1.5 mM and 
thus even higher than that mPrP(121-231), which is around 
1 mM [13,14]. Thus, recombinant mPrP(23-231) is suitable for 
structural studies by NMR, as evidenced by the one-dimen-
sional ^ - N M R spectrum in Fig. 4A. The following paper 
[27] presents a NMR study of the conformational state of 
the segment 23-120 in the full-length protein and a compar-
domain observed in mPrP(121-231) is retained in the full-
length protein, and that the amino-terminal segment 23-120 
is not significantly involved in tertiary structure formation. 
The emission maximum at 345 nm in the fluorescence spec-
tra of mPrP(23-231) (Fig. 3) indicates that most of the 7 Trp 
residues in the segment 23-120 are solvent exposed and thus 
not in a hydrophobic environment. Reference values are 320-
335 nm for tryptophans in the hydrophobic protein core, and 
348 nm for free tryptophan [25]. The single tryptophan of the 
carboxy-terminal domain, Trp145, which is also solvent ex-
posed in the three-dimensional structure [14], has an emission 
maximum of 340 nm in mPrP(121-231). 
3.3. One-dimensional 'H-NMR spectra 
A •H-NMR spectrum of mPrP(23-231) at pH 4.5 in a 
mixed solvent of 90% H2O/10% D 2 0 (Fig. 4A) shows a chem-
ical shift dispersion and resonance linewidths that are typical 
for a monomeric protein of size about 200 residues. The lines 
near 0 ppm are representative for ring current-shifted methyl 
resonances in well structured globular proteins [26]. The 30 
glycyl residues in the segment 23-120 of wPrP(23-231) give 
rise to narrow, intense lines around 4 ppm. Near 10.2 ppm a 
group of lines represents the resonances of the indole NH-
groups of the 8 Trp residues in mPrP(23-231). In accordance 
with the fluorescence properties of mPrP(23-231), the small 
chemical shift dispersion of these lines suggests that the indole 
rings are not in the interior of a densely packed structural 
element. The Fig. 4 also affords a comparison of the 
!H-NMR spectrum of mPrP(23-231) (Fig. 4A) with that of 
the isolated carboxy-terminal domain mPrP(121-231) (Fig. 
4B), for which some well separated resonances are labeled 
with the previously obtained assignments [14]. Similar pat-
terns of resonance lines near 0 ppm and from 5.0 to 6.3 ppm 
are seen in mPrP(23-231) and mPrP(121-231), which would 
F198H' 
Y162Ha 
T1830H/-
L130Q? 
L139QT 
co^H) [ppm] 
Fig. 4. One-dimensional 750 MHz 'H-NMR spectra of mPrP(23-
231) (A) and mPrP(121-231) (B). The previously established reso-
nance assignments [14] for selected well-separated peaks are indi-
cated in (B). 
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ison of the isolated carboxy-terminal domain mPrP( 121-231) 
with the corresponding polypeptide segment in mPrP(23-231). 
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